Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling

Neuropharmacology

Volumn 54, Issue 7, 2008, Pages 1051-1061

  O'Sullivan, Gerard J ^a   Dunleavy, Mark ^a   Hakansson, Kerstin ^a,b   Clementi, Mario ^b   Kinsella, Anthony ^a   Croke, David T ^a   Drago, John ^c   Fienberg, Allen A ^d   Greengard, Paul ^e   Sibley, David R ^f   Fisone, Gilberto ^b   Henshall, David C ^a   Waddington, John L ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Intra Cellular Therapies Inc   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Adenylate cyclase; DARPP 32; Dopamine D1 like receptors; ERK1 2; Knockout; Seizures

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 1 (3 METHYLPHENYL) 3 (2 PROPENYL) 1H 3 BENZAZEPINE 7,8 DIOL HYDROBROMIDE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DOPAMINE 1 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN DARPP 32; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 ALLYL 6 CHLORO 7,8 DIHYDROXY 1 (3 METHYLPHENYL) 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 3-ALLYL-6-CHLORO-7,8-DIHYDROXY-1-(3-METHYLPHENYL)-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE; AMPA RECEPTOR; BENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; PPP1R1B PROTEIN, MOUSE; SK&F 83959; THREONINE;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ELECTROCORTICOGRAPHY; FEMALE; HIPPOCAMPUS; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEIZURE; TOPOGRAPHY; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; GENETICS; METABOLISM; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REACTION TIME; SIGNAL TRANSDUCTION; TIME;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BENZAZEPINES; CORPUS STRIATUM; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; HIPPOCAMPUS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; REACTION TIME; RECEPTORS, AMPA; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D5; SEIZURES; SIGNAL TRANSDUCTION; THREONINE; TIME FACTORS;

EID: 42749084804     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.02.011     Document Type: Article

References (51)

1. Bozzi Y., Vallone D., and Borrelli E. Neuroprotective role of dopamine against hippocampal cell death. Journal of Neuroscience 20 (2000) 8643-8649
2. Cepeda C., Colwell C.S., Itri J.N., Gruen E., and Levine M.S. Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons. European Journal of Neuroscience 10 (1998) 3491-3497
3. Chen J., Rusnak M., Luedtke R.R., and Sidhu A. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. Journal of Biological Chemistry 279 (2004) 39317-39330
4. Clifford J.J., Tighe O., Croke D.T., Sibley D.R., Drago J., and Waddington J.L. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology 37 (1998) 1595-1602
5. Clifford J.J., Tighe O., Croke D.T., Kinsella A., Sibley D.R., Drago J., and Waddington J.L. Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience 93 (1999) 1483-1489
6. DeNinno M.P., Schoenleber R., MacKenzie R., Britton D.R., Asin K.E., Briggs C., Trugman J.M., Ackerman M., Artman L., Bednarz L., Bhatt R., Curzon P., Gomez E., Kang C.H., Stittsworth J., and Kebabian J.W. A68930: a potent agonist selective for the dopamine D1 receptor. European Journal of Pharmacology 199 (1991) 209-219
7. Drago J., Gerfen C.R., Lachowicz J.E., Steiner H., Hollon T.R., Love P.E., Ooi G.T., Grinberg A., Lee E.J., Huang S.P., Bartlett P.F., Jose P.A., Sibley D.R., and Westphal H. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proceeding of the National Academy of Sciences USA 91 (1994) 12564-12568
8. Ferraro T.N., Golden G.T., Smith G.G., St Jean P., Schork N.J., Mulholland N., Ballas C., Schill J., Buono R.J., and Berrettini W.H. Mapping loci for pentylenetetrazol-induced seizure susceptibility in mice. Journal of Neuroscience 19 (1999) 6733-6739
9. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W., Snyder G.L., Nishi A., Cheramy A., O'Callaghan J.P., Miller D.B., Cole D.G., Corbett R., Haile C.N., Cooper D.C., Onn S.P., Grace A.A., Ouimet C.C., White F.J., Hyman S.E., Surmeier D.J., Girault J., Nestler E.J., and Greengard P. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281 (1998) 838-842
10. Francis J., Jugloff D.G., Mingo N.S., Wallace M.C., Jones O.T., Burnham W.M., and Eubanks J.H. Kainic acid-induced generalized seizures alter the regional hippocampal expression of the rat Kv4.2 potassium channel gene. Neuroscience Letters 232 (1997) 91-94
11. Girault J.A., Valjent E., Caboche J., and Herve D. ERK2: a logical AND gate critical for drug-induced plasticity?. Current Opinion in Pharmacology 7 (2007) 77-85
12. Hakansson K., Galdi S., Hendrick J., Snyder G., Greengard P., and Fisone G. Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. Journal of Neurochemistry 96 (2006) 482-488
13. Hemmings H.C., and Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein: regional, tissue, and phylogenetic distribution. Journal of Neuroscience 6 (1986) 1469-1481
14. Hollon T.R., Bek M.J., Lachowicz J.E., Ariano M.A., Mezey E., Ramachandran R., Wersinger S.R., Soares-da-Silva P., Liu Z.F., Grinberg A., Drago J., Young III W.S., Westphal H., Jose P.A., and Sibley D.R. Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. Journal of Neuroscience 22 (2002) 10801-10810
15. Holmes A., Hollon T.R., Gleason T.C., Liu Z., Dreiling J., Sibley D.R., and Crawley J.N. Behavioral characterization of dopamine D5 receptor null mutant mice. Behavioral Neuroscience 115 (2001) 1129-1144
16. Jin L.Q., Goswami S., Cai G., Zhen X., and Friedman E. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. Journal of Neurochemistry 85 (2003) 378-386
17. Levine M.S., Altemus K.L., Cepeda C., Cromwell H.C., Crawford C., Ariano M.A., Drago J., Sibley D.R., and Westphal H. Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. Journal of Neuroscience 16 (1996) 5870-5882
18. Mangiavacchi S., and Wolf M.E. D1 dopamine receptor stimulation increases the rate of AMPA receptor insertion onto the surface of cultured nucleus accumbens neurons through a pathway dependent on protein kinase A. Journal of Neurochemistry 88 (2004) 1261-1271
19. McKhann II G.M., Wenzel H.J., Robbins C.A., Sosunov A.A., and Schwartzkroin P.A. Mouse strain differences in kainic acid sensitivity, seizure behavior, mortality, and hippocampal pathology. Neuroscience 122 (2003) 551-561
20. McNamara F.N., Clifford J.J., Tighe O., Kinsella A., Drago J., Croke D.T., and Waddington J.L. Congenic D1A dopamine receptor mutants: ethologically based resolution of behavioural topography indicates genetic background as a determinant of knockout phenotype. Neuropsychopharmacology 28 (2003) 86-99
21. Merlo D., Cifelli P., Cicconi S., Tancredi V., and Avoli M. 4-Aminopyridine-induced epileptogenesis depends on activation of mitogen-activated protein kinase ERK. Journal of Neurochemistry 89 (2004) 654-659
22. Mohajeri M.H., Madani R., Saini K., Lipp H.P., Nitsch R.M., and Wolfer D.P. The impact of genetic background on neurodegeneration and behavior in seizured mice. Genes. Brain and Behavior 3 (2004) 228-239
23. Nally R.E., Kinsella A., Tighe O., Croke D.T., Fienberg A.A., Greengard P., and Waddington J.L. Ethologically based resolution of D2-like dopamine receptor agonist-versus antagonist-induced behavioral topography in dopamine- and adenosine 3′,5′-monophosphate-regulated phosphoprotein of 32 kDa 'knockout' mutants congenic on the C57BL/6 genetic background. Journal of Pharmacology and Experimental Therapeutics 310 (2004) 1281-1287
24. O'Sullivan G.J., Roth B.L., Kinsella A., and Waddington J.L. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography. European Journal of Pharmacology 486 (2004) 273-280
25. O'Sullivan G.J., Kinsella A., Sibley D.R., Tighe O., Croke D.T., and Waddington J.L. Ethological resolution of behavioural topography and D1-like versus D2-like agonist responses in congenic D5 dopamine receptor mutants: identification of D5:D2-like interactions. Synapse 55 (2005) 201-211
26. O'Sullivan G.J., Kinsella A., Grandy D.K., Tighe O., Croke D.T., and Waddington J.L. Ethological resolution of behavioral topography and D2-like vs. D1-like agonist responses in congenic D4 dopamine receptor 'knockouts': identification of D4:D1-like interactions. Synapse 59 (2006) 107-118
27. O'Tuathaigh C.M., O'Sullivan G.J., Kinsella A., Harvey R.P., Tighe O., Croke D.T., and Waddington J.L. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport 17 (2006) 79-83
28. Pages G., Guerin S., Grall D., Bonino F., Smith A., Anjuere F., Auberger P., and Pouyssegur J. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286 (1999) 1374-1377
29. Panchalingam S., and Undie A.S. SKF83959 exhibits biochemical agonism by stimulating [(35)S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40 (2001) 826-837
30. Peacock L., and Gerlach J. Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions. Biological Psychiatry 50 (2001) 501-509
31. Rashid A.J., So C.H., Kong M.M., Furtak T., El-Ghundi M., Cheng R., O'Dowd B.F., and George S.R. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proceedings of the National Academy of Sciences USA 104 (2007) 654-659
32. Saba-El-Leil M.K., Vella F.D., Vernay B., Voisin L., Chen L., Labrecque N., Ang S.L., and Meloche S. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Report 4 (2003) 964-968
33. Shinoda S., Araki T., Lan J.Q., Schindler C.K., Simon R.P., Taki W., and Henshall D.C. Development of a model of seizure-induced hippocampal injury with features of programmed cell death in the BALB/c mouse. Journal of Neuroscience Research 76 (2004) 121-128
34. Snyder G.L., Girault J.A., Chen J.Y., Czernik A.J., Kebabian J.W., Nathanson J.A., and Greengard P. Phosphorylation of DARPP-32 and protein phosphatase inhibitor-1 in rat choroid plexus: regulation by factors other than dopamine. Journal of Neuroscience 12 (1992) 3071-3083
35. Snyder G.L., Allen P.B., Fienberg A.A., Valle C.G., Huganir R.L., Nairn A.C., and Greengard P. Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. Journal of Neuroscience 20 (2000) 4480-4488
36. Starr M.S. The role of dopamine in epilepsy. Synapse 22 (1996) 159-194
37. Starr M.S., and Starr B.S. Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 6 (1993) 27-34
38. Svenningsson P., Lindskog M., Ledent C., Parmentier M., Greengard P., Fredholm B.B., and Fisone G. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proceedings of the National Academy of Sciences USA 97 (2000) 1856-1860
39. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., and Greengard P. DARPP-32: an integrator of neurotransmission. Annual Review of Pharmacology and Toxicology 44 (2004) 269-296
40. Svenningsson P., Nairn A.C., and Greengard P. DARPP-32 mediates the actions of multiple drugs of abuse. The AAPS Journal 7 (2005) 353-360
41. Thomas G.M., and Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nature Reviews Neuroscience 5 (2004) 173-183
42. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences USA 76 (1979) 4350-4354
43. Undie A.S., Weinstock J., Sarau H.M., and Friedman E. Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. Journal of Neurochemistry 62 (1994) 2045-2048
44. Valjent E., Corvol J.C., Pages C., Besson M.J., Maldonado R., and Caboche J. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. Journal of Neuroscience 20 (2000) 8701-8709
45. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., Stipanovich A., Caboche J., Lombroso P.J., Nairn A.C., Greengard P., Herve D., and Girault J.A. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proceedings of the National Academy of Sciences USA 102 (2005) 491-496
46. Waddington J.L., Daly S.A., Downes R.P., Deveney A.M., McCauley P.G., and O'Boyle K.M. Behavioural pharmacology of 'D1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D2-like' receptors. Progress in Neuropsychopharmacology and Biological Psychiatry 19 (1995) 811-831
47. Waddington J.L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N., and Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology 181 (2005) 611-638
48. + channels contribute to spike-timing dependent long-term potentiation in hippocampal pyramidal neurons. Proceedings of the National Academy of Sciences USA 99 (2002) 8366-8371
49. Weinshenker D., and Szot P. The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacology and Therapeutics 94 (2002) 213-233
50. Yao Y., Li W., Wu J., Germann U.A., Su M.S., Kuida K., and Boucher D.M. Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. Proceedings of the National Academy of Sciences USA 100 (2003) 12759-12764
51. Yuan L.L., Adams J.P., Swank M., Sweatt J.D., and Johnston D. Protein kinase modulation of dendritic K+ channels in hippocampus involves a mitogen-activated protein kinase pathway. Journal of Neuroscience 22 (2002) 4860-4868